Repligen Corporation (NASDAQ:RGEN) has recently appointed Maggie A. Pax to its board of directors, expanding the size of the board from eight to nine members. Pax brings over 25 years of experience in leading the development and execution of growth strategies for global companies, particularly in the life sciences industry. She spent eight years at Thermo Fisher Scientific, where she served as vice president of strategy and innovation for the clinical supply chain business from 2016 to 2020.
Pax's background at Thermo Fisher includes her role as the senior director of corporate development and strategy from 2013 to 2016, where she led post-merger commercial integration for the company's acquisition of Life Technologies. She also held the position of senior director of portable analytical instrumentation from 2012 to 2013. Prior to her time at Thermo Fisher, Pax held senior leadership roles in business development, marketing, and product management at Phillips Healthcare, a leading medical device company, from 1989 to 2000.
Currently, Pax serves as an independent board director for Alimera Sciences, a pharmaceutical company listed on NASDAQ, and Jellagen, a privately-held UK company specializing in novel wound care products. She also sits on the board of the U.S. subsidiary of BioPorto A/S, a Danish-based kidney biomarker company. Additionally, Pax advises healthcare and life sciences companies on business strategy, commercial growth, and partnerships.
Repligen's chairperson of the board of directors, Karen A. Dawes, expressed enthusiasm about Pax's appointment, highlighting her extensive experience in the life sciences industry. Tony J. Hunt, the chief executive officer for Repligen, emphasized that Pax's understanding of the drivers of growth for the industry aligns with Repligen's focus areas, including key account programs, continuous innovation, and M&A integration.
Repligen Corporation is a global life sciences company focused on developing and commercializing highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company primarily serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a concentration on filtration and fluid management, chromatography, process analytics, and proteins. The company's corporate headquarters are located in Waltham, Massachusetts, with manufacturing sites in the U.S., Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
Following these announcements, the company's shares moved -0.3%, and are now trading at a price of $193.68. Check out the company's full 8-K submission here.
